PETACH TIKVA, Israel | August 20, 2007 | Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced today the successful completion of preclinical trials with CF102, the second molecule in the Company’s development pipeline, which is the basis for a drug indicated for the treatment of liver cancer and hepatitis.
The Drug is Indicated for the Treatment of Patients With Liver Cancer and Patients Infected With Hepatitis.
CF102 belongs to a chemical class of substances called nucleosides, known to act as antiviral agents. Laboratory studies conducted by the Company in collaboration with a leading laboratory at Temple University in Philadelphia show that CF102 is also active against the hepatitis virus. The number of individuals infected with hepatitis B and C worldwide is 350 million and 170 million, respectively, and these numbers are rapidly increasing in recent years. The market share is currently about USD 3 billion annually due to lack of appropriate treatments.read more
No comments:
Post a Comment